Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

43 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Medical management of metastatic bone disease.
Vasudev NS, Brown JE. Vasudev NS, et al. Curr Opin Support Palliat Care. 2010 Sep;4(3):189-94. doi: 10.1097/SPC.0b013e32833d3024. Curr Opin Support Palliat Care. 2010. PMID: 20671553 Review.
Proteomics and the search for biomarkers for renal cancer.
Craven RA, Vasudev NS, Banks RE. Craven RA, et al. Among authors: vasudev ns. Clin Biochem. 2013 Apr;46(6):456-65. doi: 10.1016/j.clinbiochem.2012.11.029. Epub 2012 Dec 7. Clin Biochem. 2013. PMID: 23228867 Review.
Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era.
Gravis G, Chanez B, Derosa L, Beuselinck B, Barthelemy P, Laguerre B, Brachet PE, Joly F, Escudier B, Harrison DJ, Laird A, Vasudev N, Ralph C, Larkin J, Lote H, Salem N, Walz J, Thomassin J, Sfumato P, Stewart GD, Boher JM; Renal Cross Channel Group. Gravis G, et al. Urol Oncol. 2016 Apr;34(4):167.e17-23. doi: 10.1016/j.urolonc.2015.10.015. Epub 2015 Dec 3. Urol Oncol. 2016. PMID: 26670200
Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
Bridgeman VL, Vermeulen PB, Foo S, Bilecz A, Daley F, Kostaras E, Nathan MR, Wan E, Frentzas S, Schweiger T, Hegedus B, Hoetzenecker K, Renyi-Vamos F, Kuczynski EA, Vasudev NS, Larkin J, Gore M, Dvorak HF, Paku S, Kerbel RS, Dome B, Reynolds AR. Bridgeman VL, et al. Among authors: vasudev ns. J Pathol. 2017 Feb;241(3):362-374. doi: 10.1002/path.4845. Epub 2016 Dec 29. J Pathol. 2017. PMID: 27859259 Free PMC article.
PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.
Buckley HL, Collinson FJ, Ainsworth G, Poad H, Flanagan L, Katona E, Howard HC, Murden G, Banks RE, Brown J, Velikova G, Waddell T, Fife K, Nathan PD, Larkin J, Powles T, Brown SR, Vasudev NS. Buckley HL, et al. Among authors: vasudev ns. BMC Cancer. 2019 Nov 14;19(1):1102. doi: 10.1186/s12885-019-6273-1. BMC Cancer. 2019. PMID: 31727024 Free PMC article. Clinical Trial.
43 results